Mounjaro Side Effects: Potentially Permanent Adverse Events Explained

Which Mounjaro side effects can be permanent?

Most reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. The serious risks the Mounjaro label flags are a small group of other adverse reactions.

Serious risks include acute pancreatitis (including hemorrhagic or necrotizing cases, some fatal), acute gallbladder disease, acute kidney injury from volume depletion, serious hypersensitivity reactions, and the thyroid C-cell tumor risk carried in the boxed warning [1]. The label reports acute gallbladder disease in 0.6% of Mounjaro-treated adults versus 0% on placebo and describes kidney-injury cases reported after marketing without giving a rate [1]. It also reports temporary worsening of diabetic retinopathy with rapid improvement in glucose control [1].

One clarification matters here. Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk; it is not labeled for weight loss [1]. The weight-management studies discussed below involved tirzepatide in people with obesity or overweight; their results should not be treated as Mounjaro adverse-reaction rates [2][3].

The boxed warning: thyroid C-cell tumors

In a two-year rat study, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, adenomas and carcinomas, at plasma exposures considered clinically relevant [1]. The label states plainly that it is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined [1].

That uncertainty has practical consequences. Mounjaro is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. The label asks prescribers to counsel patients about the potential risk and about the symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, difficulty breathing, and persistent hoarseness [1].

Routine serum calcitonin monitoring or thyroid ultrasound is described in the label as being of uncertain value for early detection, partly because calcitonin testing has low specificity and thyroid disease is common in the background population [1]. The label notes that significantly elevated calcitonin values may indicate medullary thyroid carcinoma, that patients with that disease usually have values above 50 ng/L, and that an elevated value, or a thyroid nodule found on examination or imaging, warrants further evaluation [1].

Acute pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro [1]. The label asks prescribers to watch for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, and to discontinue Mounjaro and start appropriate management if pancreatitis is suspected [1].

Hemorrhagic and necrotizing cases are named specifically in the warning [1].

Gallbladder disease

In Mounjaro placebo-controlled trials in adults, acute gallbladder disease — cholelithiasis, biliary colic and cholecystectomy combined — was reported by 0.6% of Mounjaro-treated patients and 0% of those on placebo [1]. If cholelithiasis is suspected, the label calls for gallbladder studies and clinical follow-up [1].

Cholecystectomy is surgical removal of the gallbladder, so that outcome is lasting. The 0.6% figure combines cholelithiasis, biliary colic and cholecystectomy, so it is not a surgery rate by itself [1].

Acute kidney injury from dehydration

The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Mounjaro [1]. Most reported kidney-injury cases occurred after nausea, vomiting or diarrhea led to dehydration [1]. The label asks that renal function be monitored in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].

Diabetic retinopathy

Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control, and the label advises monitoring patients with a history of diabetic retinopathy for progression [1].

Severe gastrointestinal reactions and gastroparesis

Severe gastrointestinal adverse reactions occurred in more Mounjaro-treated patients than placebo patients in the adult pool: 5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%, versus 0.9% on placebo [1]. Any gastrointestinal adverse reaction was reported by 37.1%, 39.6% and 43.6% of patients on 5, 10 and 15 mg respectively, against 20.4% on placebo, and treatment was discontinued for gastrointestinal reasons by 3.0%, 5.4% and 6.6% versus 0.4% on placebo [1].

Mounjaro is not recommended in patients with severe gastroparesis [1].

Lean mass and hair loss

In a body-composition substudy of SURMOUNT-1, 160 participants had DXA scans at baseline and week 72. Body weight fell 21.3%, fat mass fell 33.9% and lean mass fell 10.9% with tirzepatide, against 5.3%, 8.2% and 2.6% with placebo (p<0.001 for each) [2]. About 75% of the weight lost was fat mass and about 25% lean mass, in both the tirzepatide and placebo groups [2]. The substudy was small, and DXA cannot separate muscle from other lean tissue [2].

Hair loss is not listed among the adverse reactions in the Mounjaro label [1].

Other serious reactions the label lists

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported; the label directs that Mounjaro be discontinued if one is suspected, that it be treated promptly, and that the drug not be used in anyone with a previous serious hypersensitivity reaction to tirzepatide or an excipient [1]. Hypoglycemia risk rises when Mounjaro is combined with insulin or an insulin secretagogue such as a sulfonylurea, and the label suggests considering a lower dose of those drugs when Mounjaro is started [1]. Pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists, and the label asks patients to inform healthcare providers of any planned surgery or procedure [1].